What is Yarrow Bioscience Inc?
operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 206.86M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.